cagrisema cagrilintide semaglutide phase 3 2025 Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Cagrilintide–semaglutide (CagriSema) as an add-on

For example, researchers have tested BPC-157 enemas as a treatment for ulcerative colitis in a pair of clinical trials conducted by the Croatian pharmaceutical company PLIVA in the 2000s

You should speak with a provider before considering BPC-157 if you: Have a chronic medical condition Take prescription medications Have immune system concerns Have a history of cancer Are pregnant or breastfeeding Are recovering from surgery Have ongoing pain or unexplained inflammation Are using other peptides, hormones, or performance compounds BPC-157 should not replace proper diagnosis, imaging, rehab, or medical treatment for injuries

The strongest preclinical evidence supports BPC-157 use for tendon and ligament repair, gut-lining integrity in NSAID-related damage, and inflammation reduction in musculoskeletal tissues

Unlike steroid injections or pain relievers that may only mask symptoms, BPC-157 helps correct the underlying issue by enhancing your body's ability to heal itself